Tags

Type your tag names separated by a space and hit enter

Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases.
J Intern Med 2004; 255(4):448-56JI

Abstract

Insulin resistance syndrome (IRS) is associated with increased cardiovascular morbidity and mortality. IRS is becoming one of the major health problems as its prevalence grows rapidly. Accelerated atherothrombotic process in the IRS is attributed to metabolic abnormalities, inflammation and to impaired fibrinolysis due to increased plasma plasminogen activator inhibitor type 1 (PAI-1) levels. Proinflammatory cytokines may have an important role in PAI-1 overexpression, particularly in the adipose tissue. Studies in genetically modified mice indicate that PAI-1 might be involved in the aetiopathogenesis of obesity. Modifying PAI-1 expression by PAI-1 inhibitors may open a new field of research and may reveal the true role of PAI-1 in atherosclerotic and insulin resistance processes.

Authors+Show Affiliations

Laboratory of Hematology, CHU Timone, Marseille, France.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

15049879

Citation

Mavri, A, et al. "Hypofibrinolysis in the Insulin Resistance Syndrome: Implication in Cardiovascular Diseases." Journal of Internal Medicine, vol. 255, no. 4, 2004, pp. 448-56.
Mavri A, Alessi MC, Juhan-Vague I. Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases. J Intern Med. 2004;255(4):448-56.
Mavri, A., Alessi, M. C., & Juhan-Vague, I. (2004). Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases. Journal of Internal Medicine, 255(4), pp. 448-56.
Mavri A, Alessi MC, Juhan-Vague I. Hypofibrinolysis in the Insulin Resistance Syndrome: Implication in Cardiovascular Diseases. J Intern Med. 2004;255(4):448-56. PubMed PMID: 15049879.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases. AU - Mavri,A, AU - Alessi,M-C, AU - Juhan-Vague,I, PY - 2004/3/31/pubmed PY - 2004/5/7/medline PY - 2004/3/31/entrez SP - 448 EP - 56 JF - Journal of internal medicine JO - J. Intern. Med. VL - 255 IS - 4 N2 - Insulin resistance syndrome (IRS) is associated with increased cardiovascular morbidity and mortality. IRS is becoming one of the major health problems as its prevalence grows rapidly. Accelerated atherothrombotic process in the IRS is attributed to metabolic abnormalities, inflammation and to impaired fibrinolysis due to increased plasma plasminogen activator inhibitor type 1 (PAI-1) levels. Proinflammatory cytokines may have an important role in PAI-1 overexpression, particularly in the adipose tissue. Studies in genetically modified mice indicate that PAI-1 might be involved in the aetiopathogenesis of obesity. Modifying PAI-1 expression by PAI-1 inhibitors may open a new field of research and may reveal the true role of PAI-1 in atherosclerotic and insulin resistance processes. SN - 0954-6820 UR - https://www.unboundmedicine.com/medline/citation/15049879/Hypofibrinolysis_in_the_insulin_resistance_syndrome:_implication_in_cardiovascular_diseases_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0954-6820&date=2004&volume=255&issue=4&spage=448 DB - PRIME DP - Unbound Medicine ER -